Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1946 1
1947 1
1949 3
1951 1
1952 1
1955 3
1956 2
1957 3
1959 3
1960 2
1961 2
1962 2
1963 1
1964 1
1965 3
1966 6
1967 11
1968 2
1969 1
1970 4
1971 5
1972 8
1973 7
1974 13
1975 26
1976 25
1977 33
1978 27
1979 24
1980 25
1981 19
1982 16
1983 22
1984 20
1985 15
1986 14
1987 48
1988 62
1989 100
1990 102
1991 125
1992 105
1993 106
1994 123
1995 134
1996 157
1997 160
1998 198
1999 191
2000 304
2001 385
2002 392
2003 461
2004 570
2005 623
2006 678
2007 813
2008 826
2009 965
2010 1268
2011 1467
2012 1698
2013 1706
2014 1969
2015 2173
2016 3135
2017 4483
2018 5500
2019 7369
2020 11094
2021 16469
2022 18292
2023 19680
2024 21256
2025 21633
2026 62

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132,396 results

Results by year

Filters applied: . Clear all
Page 1
Pfizer's vaccine raises allergy concerns.
de Vrieze J. de Vrieze J. Science. 2021 Jan 1;371(6524):10-11. doi: 10.1126/science.371.6524.10. Science. 2021. PMID: 33384356 No abstract available.
Respiratory Syncytial Virus Infection: An Update.
Soni A, Kabra SK, Lodha R. Soni A, et al. Indian J Pediatr. 2023 Dec;90(12):1245-1253. doi: 10.1007/s12098-023-04613-w. Epub 2023 Jun 16. Indian J Pediatr. 2023. PMID: 37326948 Review.
The US FDA has approved two RSV vaccines for use in older adults (GSK's Arexvy and Pfizer's ABRYSVO)....
The US FDA has approved two RSV vaccines for use in older adults (GSK's Arexvy and Pfizer's ABRYSVO)....
Fixing the Achilles Heel of Pfizer's Paxlovid for COVID-19 Treatment.
Brewitz L, Schofield CJ. Brewitz L, et al. J Med Chem. 2024 Jul 25;67(14):11656-11661. doi: 10.1021/acs.jmedchem.4c01342. Epub 2024 Jul 5. J Med Chem. 2024. PMID: 38967233 Free PMC article. Review.
Nirmatrelvir (PF-07321332), a first-in-class inhibitor of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) main protease (M(pro)), was developed by Pfizer under intense pressure during the pandemic to treat COVID-19. A weakness of nirmatrelvir is its limite …
Nirmatrelvir (PF-07321332), a first-in-class inhibitor of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) main protease (M( …
Diagnosis, Genetics, and Therapy of Short Stature in Children: A Growth Hormone Research Society International Perspective.
Collett-Solberg PF, Ambler G, Backeljauw PF, Bidlingmaier M, Biller BMK, Boguszewski MCS, Cheung PT, Choong CSY, Cohen LE, Cohen P, Dauber A, Deal CL, Gong C, Hasegawa Y, Hoffman AR, Hofman PL, Horikawa R, Jorge AAL, Juul A, Kamenický P, Khadilkar V, Kopchick JJ, Kriström B, Lopes MLA, Luo X, Miller BS, Misra M, Netchine I, Radovick S, Ranke MB, Rogol AD, Rosenfeld RG, Saenger P, Wit JM, Woelfle J. Collett-Solberg PF, et al. Horm Res Paediatr. 2019;92(1):1-14. doi: 10.1159/000502231. Epub 2019 Sep 12. Horm Res Paediatr. 2019. PMID: 31514194 Free PMC article. Review.
The journey of a lifetime - development of Pfizer's COVID-19 vaccine.
Thorn CR, Sharma D, Combs R, Bhujbal S, Romine J, Zheng X, Sunasara K, Badkar A. Thorn CR, et al. Curr Opin Biotechnol. 2022 Dec;78:102803. doi: 10.1016/j.copbio.2022.102803. Epub 2022 Sep 1. Curr Opin Biotechnol. 2022. PMID: 36162187 Free PMC article. Review.
It would be apt to say that one of the greatest accomplishments in modern medicine has been the development of vaccines against COVID-19, which had paralyzed the entire world for more than a year. Pfizer and BioNTech codeveloped the first COVID-19 vaccine that was granted …
It would be apt to say that one of the greatest accomplishments in modern medicine has been the development of vaccines against COVID-19, wh …
Recommendations on the use of azole antifungals in hematology-oncology patients.
Azanza JR, Mensa J, Barberán J, Vázquez L, Pérez de Oteyza J, Kwon M, Yáñez L, Aguado JM, Cubillo Gracian A, Solano C, Ruiz Camps I, Fortún J, Salavert Lletí M, Gudiol C, Olave Rubio T, Solano C, García-Vidal C, Rovira Tarrats M, Suárez-Lledó Grande M, González-Sierra P, Dueñas Gutiérrez C. Azanza JR, et al. Rev Esp Quimioter. 2023 Jun;36(3):236-258. doi: 10.37201/req/013.2023. Epub 2023 Apr 5. Rev Esp Quimioter. 2023. PMID: 37017117 Free PMC article. Review.
Pfizer's puzzle.
Simons J. Simons J. Fortune. 2006 Apr 17;153(7):152-4, 156. Fortune. 2006. PMID: 16649633 No abstract available.
Comparing Moderna's mRNA-1083 and Pfizer's dual-target mRNA vaccines for influenza and COVID-19.
Akingbola A, Adegbesan A, Adegoke K, Idahor C, Mariaria P, Peters F, Salami RA, Ojo O, Nwaeze E, Abdullahi O, Chuku J. Akingbola A, et al. NPJ Vaccines. 2025 May 24;10(1):105. doi: 10.1038/s41541-025-01145-6. NPJ Vaccines. 2025. PMID: 40413212 Free PMC article. Review.
This review examines Moderna's mRNA-1083 and Pfizer/BioNTech's mRNA-1020/1030 dual-target vaccines for COVID-19 and influenza. Both utilize mRNA technology, demonstrating strong immunogenicity and favorable safety profiles. Moderna's mRNA-1083 showed superior immune respon …
This review examines Moderna's mRNA-1083 and Pfizer/BioNTech's mRNA-1020/1030 dual-target vaccines for COVID-19 and influenza. Both u …
132,396 results
You have reached the last available page of results. Please see the User Guide for more information.